Post hoc analysis of the phase 3 MORPHO trial of post-HCT gilteritinib vs placebo in FLT3-ITD AML: benefit was more likely with transplant <120 days from diagnosis and/or pre-HCT FLT3 inhibitor use, linked to higher pre-HCT MRD, likely explaining regional differences in benefit.
Secondary analysis
Levis et al. Regional practice differences significantly affect the benefit of post-HCT gilteritinib in FLT3-ITD AML